ArticleNeuropsychiatric disease and treatment2026
Plasma Sphingomyelin and Ceramide Profiles as Potential Biomarkers in Young Adults with Bipolar Depression: A Lipidomics Study.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bipolar depression (BPD) lacks reliable peripheral biomarkers for early diagnosis. Sphingomyelin (SM) and ceramide (Cer) are bioactive lipids implicated in neuronal membrane signaling, yet their diagnostic utility in young adults with BPD remains unclear. Patients and Methods: We conducted a single-center exploratory untargeted lipidomics study focusing on SM and Cer species in plasma from 26 young adults (18-26 years) with BPD at baseline and after three weeks of quetiapine and magnesium valproate treatment (BPD3w), alongside 27 sex- and age-matched healthy controls (HC). Group comparisons of total SM, total Cer, and SM/Cer ratio were performed; ROC curves assessed discriminative ability. A Venn diagram approach, followed by LASSO regression with bootstrap averaging, identified a refined candidate biomarker panel from 140 SM/Cer species. Results: Both BPD and BPD3w groups exhibited elevated total SM and Cer relative to HC, whereas the SM/Cer ratio was significantly reduced. Paired analysis revealed that total SM and the SM/Cer ratio decreased after treatment (both P < 0.05), while total Cer remained unchanged. Intersection analysis yielded 14 candidate lipids, which were further refined via LASSO regression (λ = 100) with bootstrap averaging to a 4-species panel: Cer(t20:1/24:3), Cer(d19:1/25:3), SM(t18:0/22:0), and Cer(t17:0/22:0), with an AUC of 0.975 (95% CI: 0.917-1.000), representing an unvalidated internally derived estimate pending further validation. Correlation analysis revealed that Cer(d19:1/25:3), Cer(t17:0/22:0), and SM(t18:0/22:0) were positively correlated with depressive, anxiety, and manic symptom severity (HAMD, HAMA, and YMRS). Cer(t20:1/24:3) showed a modest negatively correlation with HAMD, but not with HAMA or YMRS. Additionally, Cer(t20:1/24:3) and SM(t18:0/22:0) exhibited sex-dependent differences. Conclusion: Plasma SM and Cer profiles are altered in young adults with BPD and show a partial trend toward normalization following short-term treatment. A refined 4-species panel showed promising but internally derived discriminative performance in this exploratory study. While peripheral sphingolipid signatures may serve as potential biomarkers for BPD, these findings require validation in independent cohorts before any clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.